Alzheimer's and Diabetic Specialists Captivated by New Treatment Targeting Recently Discovered Type 3 Diabetes

Mar 16, 2011, 10:30 ET from Allegiance Equity Corporation

TORONTO, March 16, 2011 /PRNewswire/ -- Allegiance Equity Corporation (TSX VENTURE: ANQ) is proud to introduce CinGx, its revolutionary new product that helps prevent and treat Type 3 Diabetes and Alzheimer's disease. CinGx™ captured the attention of leading research scientists including Dr. William Klein, Neurobiology Professor at Northwestern University, and Dr. Marcus Cantillon, American Board Certified Neurologist and Psychiatrist.

It has recently been discovered that the brain produces insulin, and that the lack of insulin and high blood glucose are major factors impacting brain function negatively, thereby increasing the incidence and severity of Alzheimer's and Dementia, a condition known as Type 3 Diabetes. Allegiance specifically developed CinGx™ for the treatment and prevention of Type 3 Diabetes.

"We're intrigued by the claim that insulin receptor protein tyrosine kinase might be stimulated by Allegiance's formulation," said Dr. Klein.

CinGx™ combines two standardized natural extracts which act synergistically to control glucose metabolism, improve cognitive function, and simultaneously minimize the risk of developing diabetes, dementia and Alzheimer's.

Based on peer reviewed randomized controlled trials, Health Canada approved label claims and advertising for improving cardiovascular and mental health on products containing CinGx™.

These health claims include reducing blood sugar, cholesterol and triglycerides, while improving memory, cognitive function, energy and mental well-being.

Dr. Marcus Cantillon invited Allegiance to speak at the CBI's 4th Annual Alzheimer's Drug Development Summit which was chaired by Dr. Cantillon who said "...DM (Diabetes) is one of the clear metabolic risk factors for AD, perhaps through insulin signaling or secondary cardiovascular effects. After rosiglitazone and other failures, there are no metabolic treatments in sight for AD that are effective and/or do not have serious side effects. Therefore insulin receptor protein tyrosine kinase treatment for Type 3 diabetes might represent a new opportunity for long term safe prevention of AD."

Both Klein and Cantillon acknowledge the need for safe alternative treatments for Type 3 diabetes The Klein Lab at Northwestern University specializes in research on Type 3 Diabetes. Learn about Dr Klein's discoveries through ABC News-ScienCentral's videos at: and

Adding CinGx™ to any meal can enhance overall food value. It can be taken as a nutritional supplement or delivered in a wide variety of food and beverage products, potentially providing millions of dollars in licensing opportunities.

"We are fortunate for the support of Dr Klein and Dr Cantillon, both leaders in the scientific research focusing on Alzheimer's and Dementia. CinGx™ represents an opportunity similar to probiotics in yogurt," said David Solomon, President of Allegiance.


Allegiance targets and develops treatments for mass markets having clearly identified product deficiencies and dissatisfied patients who suffer widespread diseases and conditions including Diabetes, High Cholesterol, Alzheimer's and Dementia Allegiance then obtains patents and regulatory approvals.

Allegiance is listed on the Toronto Stock Exchange (TSX-V: ANQ).There are presently 6,478,588 common shares of Allegiance issued and outstanding.

The TSX Venture Exchange has not reviewed and does not accept responsibility FOR THE ADEQUACY OR ACCURACY FOR HIS PRESS RELEASE, WHICH HAS BEEN PREPARED BY MANAGEMENT.

SOURCE Allegiance Equity Corporation